Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ANGZ | ISIN: FR0013183985 | Ticker-Symbol: G49N
Tradegate
06.06.25 | 10:25
0,204 Euro
-2,86 % -0,006
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENSIGHT BIOLOGICS SA Chart 1 Jahr
5-Tage-Chart
GENSIGHT BIOLOGICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,2000,20118:21
0,2010,20118:11

Aktuelle News zur GENSIGHT BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.05.GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025326Regulatory News: The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing...
► Artikel lesen
23.04.GenSight Biologics Annual General Meeting on May 13, 2025457Procedures for obtaining preparatory documents for the General Meeting Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused...
► Artikel lesen
08.04.GenSight Biologics S.A.: GenSight Biologics Announces the Filing of its 2024 Universal Registration Document396Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal...
► Artikel lesen
07.04.GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update346Operations funded until early June 2025 as a result of disciplined spending controls Discussions with French agency ANSM regarding the early access program (AAC) for LUMEVOQ progressing ...
► Artikel lesen
19.03.GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates410Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal...
► Artikel lesen
GENSIGHT BIOLOGICS Aktie jetzt für 0€ handeln
17.03.GenSight Biologics Announces LUMEVOQ Scientific Updates at NANOS 2025277Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative...
► Artikel lesen
07.03.GenSight Biologics Announces Financing Amounting to c. €0.9 Million from Existing Investors417Regulatory News: This press release is not being made in and copies of It may not be distributed or sent, directly or indirectly, into the United States, Canada, South Africa, Japan or Australia GenSight...
► Artikel lesen
28.02.GenSight Biologics S.A. reports FY results1
27.02.GenSight Biologics S.A.: GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results593Review of LUMEVOQ® dossier to resume compassionate access program in France is ongoing; in parallel, work continues on the new RECOVER Phase III clinical trial and marketing application to the...
► Artikel lesen
12.02.GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ Gene Therapy at the Conclusion of the REFLECT Study330Sustained efficacy 5 years after injection in REFLECT Phase III trial Continued benefit at 5 years in bilaterally treated patients: clinically meaningful improvement of at least 15 letters...
► Artikel lesen
23.01.GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update467Capital increases in late 2024 provide sufficient working capital until expected resumption of early access program in February. Review of LUMEVOQ dossier ongoing, following submission...
► Artikel lesen
15.01.GenSight Biologics Reveals Positive 5-Year Outcomes For Patients Treated Unilaterally With LUMEVOQ-
15.01.GenSight Biologics S.A.: GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ Gene Therapy344Five years after the one-time injection, patients with Leber Hereditary Optic Neuropathy (LHON) due to the MT-ND4 gene variant demonstrated sustained bilateral improvement in visual acuity and...
► Artikel lesen
24.12.24GenSight Biologics S.A.: GenSight Biologics announces a financing for an amount of c. €1.5 million from existing investors614THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA Regulatory News:...
► Artikel lesen
18.12.24GenSight Biologics S.A.: GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation413Ongoing communication with French medicines safety agency ANSM on early access dossier for LUMEVOQ First injections expected in January 2025 Advanced discussions to secure financing...
► Artikel lesen
13.11.24GenSight Biologics S.A.: GenSight Biologics Announces Submission of LUMEVOQ Dossier to ANSM to Prepare for Restart of Early Access Program in France412Updated file will support medicines safety agency's review of individual applications for early access (AAC) use First injections expected in December 2024 Regulatory News: GenSight...
► Artikel lesen
01.11.24GenSight Biologics announces a financing for an amount of c. €2.8 million from existing investors669Regulatory News: This press release is not being made in and copies of It may not be distributed or sent, directly or indirectly, into the United States, Canada, South Africa, Japan or Australia GenSight...
► Artikel lesen
28.10.24GenSight Biologics S.A.: GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ409Patients treated with LUMEVOQ gene therapy experience better visual outcomes than idebenone-treated patients and untreated patients Most comprehensive analysis of visual outcomes to date...
► Artikel lesen
24.10.24GenSight Biologics S.A.: GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update469Cash position amounts to €3.4 million as of September 30, 2024. LUMEVOQ drug product has passed all quality control tests; submission to ANSM supporting AAC resumption now scheduled for...
► Artikel lesen
17.10.24GenSight Biologics Announces LUMEVOQ Scientific Updates at AAO 2024410Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative...
► Artikel lesen
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1